Cargando…
Rational Combinations of Targeted Agents in AML
Despite modest improvements in survival over the last several decades, the treatment of AML continues to present a formidable challenge. Most patients are elderly, and these individuals, as well as those with secondary, therapy-related, or relapsed/refractory AML, are particularly difficult to treat...
Autores principales: | Bose, Prithviraj, Grant, Steven |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470160/ https://www.ncbi.nlm.nih.gov/pubmed/26113989 http://dx.doi.org/10.3390/jcm4040634 |
Ejemplares similares
-
Coordinate PI3K pathway and Bcl-2 family disruption in AML
por: Bose, Prithviraj, et al.
Publicado: (2012) -
Emerging agents and regimens for AML
por: Liu, Hongtao
Publicado: (2021) -
Computational Approaches to the Rational Design of Tubulin-Targeting Agents
por: Pérez-Peña, Helena, et al.
Publicado: (2023) -
Clinical Results of Hypomethylating Agents in AML Treatment
por: Cruijsen, Marjan, et al.
Publicado: (2014) -
Rational combinations of immunotherapeutics that target discrete pathways
por: Spranger, Stefani, et al.
Publicado: (2013)